<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624546</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB18199</org_study_id>
    <secondary_id>rsrb18199</secondary_id>
    <nct_id>NCT00624546</nct_id>
  </id_info>
  <brief_title>Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD</brief_title>
  <official_title>Effect of Antireflux Therapy on the Expression of Genes Known to be Important in Inflammation, Metaplasia and Neoplasia in Patients With GERD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the symptomatic and epithelial (histologic and endoscopic) response to antireflux&#xD;
      therapy are well known and extensively studied, little is known of the genetic events&#xD;
      occurring in response to proton pump inhibitor therapy. Preliminary data from our laboratory&#xD;
      has shown, for example, that COX-2 expression is not only elevated in patients with&#xD;
      gastroesophageal reflux disease but also can be correlated with pathologic esophageal acid&#xD;
      exposure on 24 hour pH monitoring. Similar studies have suggested that antireflux surgery may&#xD;
      normalize COX-2 gene expression. In contrast studies following ablation of dysplastic&#xD;
      Barrett's epithelium have shown persistence of genetic changes associated with altered&#xD;
      cellular function, despite the return of the histologic appearance to normal. Several key&#xD;
      mediators of inflammation, metaplasia (Barrett's) and neoplasia have now been well&#xD;
      characterized and shown to be important factors in the pathogenesis of esophageal injury. It&#xD;
      is likely that successful antireflux therapy returns altered expression of these mediators&#xD;
      toward normal although this hypothesis remains largely unexplored. The aim of this study is&#xD;
      to investigate gene expression of key mediators of the spectrum of esophageal mucosal injury&#xD;
      and the response to antireflux therapy.&#xD;
&#xD;
      Hypothesis: Antireflux therapy (proton pump inhibitor and surgical fundoplication) normalizes&#xD;
      the expression of genes known to be involved in the pathogenesis of inflammation&#xD;
      (esophagitis), metaplasia (Barrett esophagus) and neoplasia (adenocarcinoma).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims: To determine the effects of antireflux therapy (pump inhibitor and surgical&#xD;
      fundoplication) on gene expression of:&#xD;
&#xD;
        1. inflammation: IL-8, IFN-g, TNF-a.&#xD;
&#xD;
        2. intestinal metaplasia: CDX-1/2, MUC2 and Sonic hedgehog.&#xD;
&#xD;
        3. Neoplasia: Cox-2, VEGF, and EGFR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Expected recruitment numbers have not been achieved.&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>gene expression</measure>
    <time_frame>before and after treatment</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>GERD</condition>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>gerd patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>non gerd controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevacid Solutabs</intervention_name>
    <description>BID Prevacid Solutabs</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Antireflux surgery</intervention_name>
    <description>Lap Nissen</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Esophageal mucosal biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects: (a) 20 patients with GERD and (b) 20 non-GERD controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For patients with GERD&#xD;
&#xD;
          -  Patients referred for anti-reflux surgery&#xD;
&#xD;
          -  On PPI therapy for at least 6 months&#xD;
&#xD;
          -  Positive ambulatory pH monitoring (%time pH&lt;4 &gt; 4.7)&#xD;
&#xD;
          -  Age greater than 18 years old.&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
        For non-GERD controls&#xD;
&#xD;
          -  Negative ambulatory pH monitoring OR&#xD;
&#xD;
          -  Upper endoscopy performed for non-GERD symptoms.&#xD;
&#xD;
          -  Age greater than 18 years old.&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior foregut surgery&#xD;
&#xD;
          -  Contra-indications for operation (poor clinical status, etc.)&#xD;
&#xD;
          -  Contra-indications for endoscopy and biopsy (esophageal or gastric varices,&#xD;
             therapeutic anticoagulation with Coumadin or Heparin, etc.)&#xD;
&#xD;
          -  Unwillingness to participate in all of the follow-up studies&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients using medications that may interfere with PPIs pharmacokinetics (sucralfate,&#xD;
             ketoconazole (Nizoral), ampicillin (Omnipen, Principen), digoxin (Lanoxin,&#xD;
             Lanoxicaps), and iron (Feosol, Mol-Iron, Fergon, Femiron).&#xD;
&#xD;
          -  Patients using medications that may interfere with gene expression&#xD;
             (Immunosuppressants, Aspirin, NSAIDs, Corticosteroids).&#xD;
&#xD;
          -  Patients with diseases that may interfere with gene expression (autoimmune diseases,&#xD;
             diseases that course with immunosuppression).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey H Peters</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jeffrey H Peters</investigator_full_name>
    <investigator_title>Professor and Chair of the Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>gastroesophageal reflux</keyword>
  <keyword>antireflux surgery</keyword>
  <keyword>Barrett's</keyword>
  <keyword>Esophagus</keyword>
  <keyword>Esophagitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

